Critics say stem cell panel skirting the law; Board didn't give proper notice of meeting, they say
By San Francisco Chronicle,
San Francisco Chronicle
| 12. 16. 2004
Even before its first meeting, the board being created to direct California's $3 billion stem cell program is stirring up controversy about whether it is complying with the state's open-government rules.
Terry Francke, general counsel of a Sacramento public interest group called Californians Aware, urged state Attorney General Bill Lockyer to delay the inaugural meeting of the stem cell board, scheduled for Friday in San Francisco.
In a letter to Lockyer, Francke gave his "strong endorsement" of a protest filed by Charles Halpern, an independent public interest lawyer in Berkeley who is alleging the official agenda and public notice for the Friday meeting fail to comply with the state Bagley-Keene Act, which mandates open meetings of public agencies.
Halpern previously had tried to win a seat on the board, known as the Independent Citizens Oversight Committee. Although that didn't happen, Halpern said he still intends to make his views known as the stem-cell enterprise gets under way.
Halpern asserted that planners of the Friday meeting did not provide enough advance notice, gave only cursory descriptions of agenda items, provided no...
Related Articles
By Gregory Laub and Hannah Glaser, MedPage Today | 08.07.2025
In this MedPage Today interview, Leigh Turner, PhD, a professor of health policy and bioethics at the University of California Irvine, unpacks the growing influence of stem cell clinics and the blurred line between medicine and marketing. He explains how...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...
By Christina Jewett, The New York Times | 06.05.2025
Health Secretary Robert F. Kennedy Jr. recently declared that he wanted to expand access to experimental therapies but conceded that they could be risky or fraudulent.
In a podcast with Gary Brecka, who describes himself as a longevity expert...
By Mike Baker, The New York Times | 02.25.2025
As investigators struggled for weeks to find who might have committed the brutal stabbings of four University of Idaho students in the fall of 2022, they were focused on a key piece of evidence: DNA on a knife sheath that...
